Comparing Bioasis Technologies (OTCMKTS:BIOAF) and Prelude Therapeutics (NASDAQ:PRLD)

Bioasis Technologies (OTCMKTS:BIOAF) and Prelude Therapeutics (NASDAQ:PRLD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Bioasis Technologies and Prelude Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioasis Technologies	0	0	0	0	0.00
Prelude Therapeutics	1	0	2	0	2.33

Prelude Therapeutics has a consensus price target of $5.50, indicating a potential upside of 18.15%. Given Prelude Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than Bioasis Technologies.

Insider and Institutional Ownership

79.7% of Prelude Therapeutics shares are held by institutional investors. 63.9% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Bioasis Technologies and Prelude Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioasis Technologies	N/A	N/A	N/A
Prelude Therapeutics	N/A	-129.98%	-80.85%

Risk and Volatility

Bioasis Technologies has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Earnings & Valuation

This table compares Bioasis Technologies and Prelude Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioasis Technologies	N/A	N/A	N/A	N/A	N/A
Prelude Therapeutics	$12.14 million	24.16	-$99.50 million	($1.29)	-3.61

Bioasis Technologies has higher earnings, but lower revenue than Prelude Therapeutics.

Summary

Prelude Therapeutics beats Bioasis Technologies on 7 of the 9 factors compared between the two stocks.

About Bioasis Technologies

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.